Madrigal Pharmaceuticals (MDGL) EBT (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of EBT data on file, last reported at -$92.3 million in Q1 2026.

• On a quarterly basis, EBT fell 26.03% year-over-year to -$92.3 million in Q1 2026; TTM through Mar 2026 was -$417.6 million, a 10.48% decrease from a year earlier, with the FY2025 full-year figure at -$853.8 million, up 11.07% from the prior year.
• EBT for Q1 2026 stood at -$92.3 million, up from -$172.0 million in the prior quarter.
• Over the last five years, EBT for MDGL reached as high as -$42.2 million in Q2 2025 and fell as low as -$172.0 million in Q4 2025.
• Historically, EBT has averaged -$94.8 million across 5 years, with a median of -$85.9 million in 2022.
• On a YoY basis, EBT climbed as much as 72.21% in 2025 and fell as far as 275.12% in 2025.
• Year by year, EBT stood at -$85.9 million in 2022, then sank by 30.6% to -$112.2 million in 2023, then surged by 59.14% to -$45.8 million in 2024, then tumbled by 275.12% to -$172.0 million in 2025, then soared by 46.33% to -$92.3 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$92.3 million in Q1 2026, -$172.0 million in Q4 2025, and -$111.1 million in Q3 2025.